{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:37:04Z","timestamp":1789043824742,"version":"build-2803163510"},"reference-count":95,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The nucleos(t)ide analogues (NAs) entecavir (ETV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are preferred treatment options for patients with chronic hepatitis B infection (CHB). However, resistance to ETV has been reported, especially with prior exposure to other NAs, and long\u2010term TDF treatment has been associated with decline in renal function and loss of bone mineral density in some patients. Consequently, TAF may be preferable to ETV, TDF or other NAs in specific circumstances such as in patients with risk of bone or renal complications, elderly patients or those with previous NA experience.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To provide a summary of the available efficacy and safety data following switch to TAF from other NAs in patients with CHB in clinical studies and real\u2010world settings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Literature searches were performed on PubMed and abstracts from three major international liver congresses between 2019 and 2021. Studies that included efficacy and\/or safety data for patients with CHB switching from any NA to TAF were selected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty\u2010six papers and abstracts were included in this narrative review. Switching from TDF to TAF maintained or improved virological and biochemical responses with improved bone and renal safety. Switching from ETV or other NAs to TAF maintained or improved virological and biochemical responses and varying results for bone and renal safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Switching to TAF appears to maintain or improve virological, biochemical and bone\u2010 and renal\u2010related safety outcomes. These data support the concept of switching to TAF in some patients with CHB based on their individual circumstances.<\/jats:p><\/jats:sec>","DOI":"10.1111\/apt.16788","type":"journal-article","created":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T06:03:52Z","timestamp":1645164232000},"page":"921-943","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Review article: switching patients with chronic hepatitis B to tenofovir alafenamide\u2014a review of current data"],"prefix":"10.1111","volume":"55","author":[{"given":"Young\u2010Suk","family":"Lim","sequence":"first","affiliation":[{"name":"University of Ulsan College of Medicine  Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9012-313X","authenticated-orcid":false,"given":"Wai\u2010Kay","family":"Seto","sequence":"additional","affiliation":[{"name":"The University of Hong Kong  Hong Kong"},{"name":"The University of Hong Kong\u2010Shenzhen Hospital  Shenzen China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Kurosaki","sequence":"additional","affiliation":[{"name":"Musashino Red Cross Hospital  Musashino Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Fung","sequence":"additional","affiliation":[{"name":"University of Toronto  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2442-7952","authenticated-orcid":false,"given":"Jia\u2010Horng","family":"Kao","sequence":"additional","affiliation":[{"name":"National Taiwan University Hospital  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8230-8583","authenticated-orcid":false,"given":"Jinlin","family":"Hou","sequence":"additional","affiliation":[{"name":"Nanfang Hospital Southern Medical University  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart C.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Henry Ford Health System and Wayne State University School of Medicine  Detroit MI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Flaherty","sequence":"additional","affiliation":[{"name":"Gilead Sciences  Foster City CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0369-5878","authenticated-orcid":false,"given":"Leland J.","family":"Yee","sequence":"additional","affiliation":[{"name":"Gilead Sciences  Foster City CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Gilead Sciences  Foster City CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosh","family":"Agarwal","sequence":"additional","affiliation":[{"name":"King's College Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1026-7476","authenticated-orcid":false,"given":"Pietro","family":"Lampertico","sequence":"additional","affiliation":[{"name":"Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico  Milan Italy"},{"name":"University of Milan  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,2,17]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"World Health Organization.Hepatitis B fact sheet. Published online 27. July 2020. Accessed 25 November 2020.https:\/\/www.who.int\/news\u2010room\/fact\u2010sheets\/detail\/hepatitis\u2010b"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy598"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9675-4"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2019.1002"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30246"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15867"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30833"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.4103\/sjg.SJG_447_18"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000511585"},{"key":"e_1_2_7_13_1","first-page":"938","article-title":"The guidelines of prevention and treatment for chronic hepatitis B [2019 version]","volume":"27","author":"Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association","year":"2019","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13504"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2011.01533.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-012-2402-2"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28916"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.02.006"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13397"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.11.039"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2012.05093.x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009756"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.5009\/gnl18183"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-014-3363-4"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.11.001"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.08.008"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu471"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.06.023"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.5.1898-1906.2005"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp3002045"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00128-15"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.10.035"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30107-8"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30024-3"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(20)32206-6"},{"key":"e_1_2_7_36_1","unstructured":"LauG.APASL HBV reactivation 2021 Guidelines. Presented on 6 February 2021 at APASL 2021 Bangkok (Virtual Meeting). Accessed 27 April 2021.https:\/\/www.youtube.com\/watch?v=fbpVoQX1hYk"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30421-2"},{"key":"e_1_2_7_38_1","first-page":"301A","article-title":"Safety and efficacy at 48 weeks after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in chronic HBV patients with risk factors for TDF use","volume":"70","author":"Buti M","year":"2019","journal-title":"Hepatology"},{"key":"e_1_2_7_39_1","first-page":"S87","article-title":"48\u2010week safety and efficacy of switching to tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF) in chronic HBV Asian patients with TDF risk factors (RF)","volume":"14","author":"Ahn SH","year":"2020","journal-title":"Hepatol Int"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(20)30670-X"},{"key":"e_1_2_7_41_1","first-page":"S54","article-title":"96\u2010week efficacy and safety of tenofovir disoproxil fumarate to tenofovir alafenamide switch vs continued TDF treatment among virologically\u2010suppressed hepatitis B patients of Asian ethnicity","volume":"15","author":"Ahn SH","year":"2021","journal-title":"Hepat Int"},{"key":"e_1_2_7_42_1","first-page":"S54","article-title":"Pisagor cohort: tenofovir alafenamide real life data in hepatitis B","volume":"14","author":"Atelan MK","year":"2020","journal-title":"Hepatol Int"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.04.045"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13053"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13500"},{"key":"e_1_2_7_46_1","first-page":"497A","article-title":"Tenofovir disoproxil fumarate switching to tenofovir alafenamide for 2 years resulted in both ALT and AST, and APRI score improvement in patients with chronic hepatitis B","volume":"72","author":"Huynh T","year":"2020","journal-title":"Hepatology"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14686"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12481"},{"key":"e_1_2_7_49_1","first-page":"481A","article-title":"Early changes in proximal tubule markers in CHB patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide according to EASL 2017 criteria: a real\u2010life study","volume":"72","author":"Loglio A","year":"2020","journal-title":"Hepatology"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13451"},{"key":"e_1_2_7_51_1","first-page":"S309A","article-title":"Longer\u2010term experience with tenofovir alafenamide (TAF) in HBV\u2010infected patients; changes in eGFR, FIB4, ALT, and DNA suppression","volume":"70","author":"Reddy R","year":"2019","journal-title":"J Hepatol"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31793"},{"key":"e_1_2_7_53_1","first-page":"295A","article-title":"Improvement in virologic, biochemical and renal outcomes in chronic hepatitis B (CHB) patients switched to tenofovir alafenamide (TAF) in routine clinical practice","volume":"70","author":"Yeh ML","year":"2019","journal-title":"Hepatology"},{"key":"e_1_2_7_54_1","first-page":"490A","article-title":"Maintenance of high levels of viral suppression and improved safety profile of tenofovir alafenamide relative to tenofovir disoproxil fumarate in chronic hepatitis B patients treated for 5 years in two ongoing phase 3 studies","volume":"72","author":"Chan H","year":"2020","journal-title":"Hepatology"},{"key":"e_1_2_7_55_1","first-page":"H\u201028","article-title":"Real\u2010world outcomes of sequential therapy with tenofovir alafenamide following long\u2010term entecavir","volume":"15","author":"Arai T","year":"2021","journal-title":"Hepatol Int"},{"key":"e_1_2_7_56_1","first-page":"H\u201043","article-title":"Switching to tenofovir alafenamide (TAF) from entecavir in Chinese chronic hepatitis B (CHB) patients","volume":"15","author":"Chen P","year":"2021","journal-title":"Hepatol Int"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25515"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12443"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14786"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14482"},{"key":"e_1_2_7_61_1","first-page":"H\u201040","article-title":"Sequential therapy with tenofovir alafenamide (TAF) in patients with chronic hepatitis B (CHB): an interim analysis of an ongoing multinational propsective study","volume":"15","author":"Ogawa E","year":"2021","journal-title":"Hepatol Int"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25644"},{"key":"e_1_2_7_63_1","first-page":"H\u201036","article-title":"Significance of switching from ETV to TAF for CHB patients with suboptimal response to ETV: a retrospective cohort study","volume":"15","author":"Yan D","year":"2021","journal-title":"Hepatol Int"},{"key":"e_1_2_7_64_1","first-page":"316A","article-title":"Safety and efficacy of switching to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: Week 24 results from a Phase 2 study","volume":"70","author":"Lim YS","year":"2019","journal-title":"Hepatology"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(20)32187-5"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(20)32176-0"},{"key":"e_1_2_7_67_1","first-page":"e10380","article-title":"Clinical characteristics of hepatitis B virus patients after switching to tenofovir alafenamide fumarate: a retrospective observational study","volume":"12","author":"Alghamdi AS","year":"2020","journal-title":"Cureus"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620\u2010021\u201007033\u2010y"},{"key":"e_1_2_7_69_1","first-page":"496A","article-title":"Switching from prior nucleos(t)ide analogues (NAs) to tenofovir alafenamide alone in patients with chronic hepatitis B in clinical practice","volume":"72","author":"Komorizono Y","year":"2020","journal-title":"Hepatology"},{"key":"e_1_2_7_70_1","first-page":"12","article-title":"Short\u2010term efficacy after switching from adefovir dipivoxil and tenofovir disoproxil fumarate therapy to tenofovir alaferamide for chronic hepatitis B","volume":"14","author":"Sano T","year":"2021","journal-title":"Biomed Rep"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.05.057"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(20)32196-6"},{"key":"e_1_2_7_73_1","first-page":"H\u201002","article-title":"A real\u2010world clinical study of lipid changes on TAF treatment in Chinese chronic hepatitis B patients with diabetes mellitus","volume":"15","author":"Zhao J","year":"2021","journal-title":"Hepatol Int"},{"key":"e_1_2_7_74_1","first-page":"308A","article-title":"Differential tenofovir alafenamide (TAF) adoption in HBV\u2010infected populations; assessment of care in US clinical practice","volume":"70","author":"Curry M","year":"2019","journal-title":"Hepatology"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1247"},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13418"},{"key":"e_1_2_7_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2020.06.037"},{"key":"e_1_2_7_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16043"},{"key":"e_1_2_7_79_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1939"},{"key":"e_1_2_7_80_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-021-10235-1"},{"key":"e_1_2_7_81_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.02.007"},{"key":"e_1_2_7_82_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ296"},{"key":"e_1_2_7_83_1","first-page":"757","article-title":"Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention","volume":"5","author":"Mill\u00e1n J","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"e_1_2_7_84_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1753-4887.1996.tb03903.x"},{"key":"e_1_2_7_85_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a010167"},{"key":"e_1_2_7_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12990"},{"key":"e_1_2_7_87_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26180"},{"key":"e_1_2_7_88_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29537"},{"key":"e_1_2_7_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.06.006"},{"key":"e_1_2_7_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.01.007"},{"key":"e_1_2_7_91_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13253"},{"key":"e_1_2_7_92_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.03.048"},{"key":"e_1_2_7_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.05.009"},{"key":"e_1_2_7_94_1","first-page":"S53","article-title":"Projection of health outcomes over 5\u2010year and 10\u2010year period using tenofovir alafenamide (TAF) for the management of chronic hepatitis B (CHB) in China","volume":"13","author":"Han Y","year":"2019","journal-title":"Hepatol Int"},{"key":"e_1_2_7_95_1","unstructured":"HanY YuB HuM HouF YangY WangL.Projection of long\u2010term bone and renal outcomes using tenofovir alafenamide (TAF) for the management of chronic hepatitis B (CHB) in China. Poster P\u201052 presented at APASL STC 2019."},{"key":"e_1_2_7_96_1","first-page":"85","article-title":"Projection of 10\u2010year liver, bone, and renal outcomes using tenofovir alafenamide for the management of chronic hepatitis B in Taiwan","volume":"13","author":"Su TH","year":"2019","journal-title":"Gut Liver"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.16788","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/apt.16788","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.16788","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T16:38:55Z","timestamp":1692722335000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.16788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,17]]},"references-count":95,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1111\/apt.16788"],"URL":"https:\/\/doi.org\/10.1111\/apt.16788","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,17]]},"assertion":[{"value":"2021-08-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}